
    
      Primary Objectives

      The primary study objectives, in patients with locally advanced, unresectable Stage III NSCLC
      treated with durvalumab as part of the UK EAP or non-EAP, are:

        1. To describe clinical outcomes

        2. To describe the patient demographic and clinical characteristics Secondary Objective

      1. To describe treatment patterns of durvalumab
    
  